CN103040856A - Medicine composition for treating varicella zoster virus disease - Google Patents
Medicine composition for treating varicella zoster virus disease Download PDFInfo
- Publication number
- CN103040856A CN103040856A CN2012105708277A CN201210570827A CN103040856A CN 103040856 A CN103040856 A CN 103040856A CN 2012105708277 A CN2012105708277 A CN 2012105708277A CN 201210570827 A CN201210570827 A CN 201210570827A CN 103040856 A CN103040856 A CN 103040856A
- Authority
- CN
- China
- Prior art keywords
- medicine composition
- zoster virus
- varicella zoster
- cured
- virus disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicine composition for treating a varicella zoster virus disease. The medicine composition is characterized by being prepared from the following components: VitB6, dexamethasone, anisodamine, procaine, VitB12, virazole and normal saline, and the weight ratio of the components is (0.2-0.4):(0.01-0.04):(0.01-0.02):(0.04-0.2):(0.0005-0.003):(0.1-0.2):(50-100). After the medicine composition is injected once, 444 patients are cured, which accounts for 85%; after the medicine composition is injected twice, 51 patients are cured, which accounts for 9.7%; after the medicine composition is injected for three times, 26 patients are cured, which accounts for 5%; one patient is cured after being injected for four times, and the cure rate is more than 99%; and the longest time that pains go away is 30 days, the shortest time is only several hours, and the average value is 7.5 days.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, especially a kind of pharmaceutical composition for the treatment of the varicella zoster virus disease.
Background technology
Herpesvirus (Herpes-Virus) is the common pathogenic microorganism of animal and human's apoplexy due to endogenous wind, varicella zoster virus (Vaircella-Zoster Virus wherein, VZV) be common pathogen, VZV infects can cause taped blister examine disease, be a viral disease that kind is involved nerve-skin, motherland's medical science is called the skirt-roof Serpentis.This disease is often multiple with spring and autumn, and traditional smelting is treated this sick method generally with pain relieving, antiinflammatory, prevents from secondary infection and shorten the course of disease as far as possible being the Therapeutic Principle, without special Therapeutic Method, so treatment time is long, and expense is high, sequela is many, unsatisfactory curative effect, and some patients have pain to reach more than 1 year.Eighties of last century the seventies people study and have found vidarabine, and particularly after acyclovir (Acv, acycloguanosine) in 1977 appearance, the medicine of anti-herpesvirus is really starting.Although oneself becomes the second filial generation broad-spectrum antiviral medicament of large usage quantity present acyclovir and famciclovir (FCV), to the poor effect of varicella zoster virus.Although motherland's medical science has pair varicella zoster virus that the report of certain curative effect is arranged, pharmaceutical composition and the product method thereof for the treatment of herpesvirus are disclosed such as Chinese patent 03128003.x, the compositions that it is made of 50-80% Herba Hyperici perforati extract and 20-50% lysine hydrochloride, can suppress Viral infection, recurrence and raising immunity of organisms, it has the effect of anti-herpesvirus.But responding time is long, and curative effect waits checking.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art, the pharmaceutical composition of a kind of short treating period, treatment varicilla-zoster virus disease that curative effect is high is provided.Purpose of the present invention realizes by following technical proposals, and the present invention is formulated by following component and weight ratio; VitB6: dexamethasone: Anisodamine: general the State of Lu caine: VitB12: virazole: normal saline=0.2-0.4:0.01-0.04:0.01-0.02:0.04-0.2:0.0005-0.003:0.1-0. 2:50-100.
Described procaine can be substituted by lignocaine.
The present invention is the pharmaceutical composition that the existing medicine of ingenious utilization carries out the combination of effective science, VitB6 is the coenzyme that consists of amino acid transaminase and decarboxylase in the component of the present invention, it participates in amino acid metabolism, and participate in the synthetic of blood red white gamma-amino acid of dawn, be conducive to the body metabolism and accelerate, with the collaborative immunocompetence that improves body of other component.The simultaneously effect of nutritious nerve; dexamethasone mainly is antiinflammatory and removes edema; Anisodamine is Cell protection; improve cell to the toleration of anoxia; and Cell protection film; promote simultaneously local blood circulation; accelerate the reparation of focal zone; general the State of Lu caine has the painful effect in town; and antioxidation and trophic nerve effect are arranged, VitB12 is the important substance that human body is kept cell division, and homocysteine is transformed in the methylthio-aminoacids process; make simultaneously the N5-methyl tetrahydrofolate change tetrahydrofolic acid into; and tetrahydrofolic acid participates in multiple biochemical metabolism process, as the synthetic of purine nucleotides and pyrimidine nucleotide with transform and promote some amino acid whose conversion and change, be conducive to produce in the body antiviral internal environment; improve body immunity, make varicella zoster virus be difficult in vivo existence and breeding.While is nutritious function of nervous system also, and virazole mainly is kill virus.The present invention not only makes each component bring into play each self-applying, makes the synergism between them very outstanding by combination, has guaranteed that compositions has higher curative effect and the shorter course for the treatment of to the varicella zoster virus disease.
The present invention observes through clinic trial, and effect is very good, treats altogether patient's 522 examples in clinical, male's 326 examples wherein, and women's 196 examples make 88 years old the most all the year round, and make 8 months off year.444 examples through present composition injection is once cured account for 85%, and 51 examples that the injection secondary is cured account for 9.7%, inject 26 examples of three recoveries from illness, account for four afterwards recoveries from illness of 5%, 1 example injection.Cure rate surpasses 99%.What the pain disappearance was the slowest is 30 days, and the fastest only a few hours, meansigma methods is 7.5 days.None example has complication and sequela.
Model case: 1, the king * *, woman, 64 years old, the four groups of people in Shi Si village, Nong Xing township, Pengxi County, Sichuan Province, the peasant, in June, 2010 is because suffering from taped blister examine disease, the poor effect of seeking medical advice everywhere, hurt like hell, came here medical on June 14, through annotating once with present composition local subcutaneous point, pain disappears after three hours, skin lesion district exudate reduces, and second day skin lesion district begins the incrustation healing.Decrustation recovery from illness after five days.
2, shut out *, the man, 71 years old, three groups of people of Nanchong City Jialing District Ji'an Zhen Shicun, the peasant, because suffering from taped blister examine disease multi-treatment poor effect, the here of coming on February 19th, 2011 is medical, through the subcutaneous injection present composition, second day begins skin lesion position exudate and reduces, through the subcutaneous injection present composition second time, the 3rd day begins incrustation, decrustation recovery from illness after 7 days.
Using method of the present invention is: (skin lesion scope heart is as far as possible without the strong disinfectant of zest) draws the present composition with 20-50 milliliter needle tubing under the strict sterilization drape, with No. 5 or 16-20 syringe needle by make gradually Intradermal or subcutaneous injection around the skin lesion position to the center, cover whole skin lesion district during injection as far as possible, do not stay the blind area, inject and be coated with Gentian Violet liquid medicine after complete.General injection shot is controlled within the 50-80 milliliter.
The specific embodiment
Embodiment 1, gets the raw materials ready by following component and weight ratio; VitB6 200g, dexamethasone 10g, Anisodamine 10g, general the State of Lu caine 40 g, VitB12 0.5 g, virazole 100 g, normal saline 50000 g.With above-mentioned each component mix homogeneously, divide to be filled in the glass notes bottle, the rear storage of sterilizing methods sterilization gets final product routinely.
Embodiment 2, get the raw materials ready by following component and weight ratio; VitB6 300g, dexamethasone 30g, Anisodamine 15g, general the State of Lu caine 100 g, VitB12 2 g, virazole 150 g, normal saline 100000 g.With above-mentioned each component mix homogeneously, divide to be filled in the glass notes bottle, the rear storage of sterilizing methods sterilization gets final product routinely.
Embodiment 3, get the raw materials ready by following component and weight ratio; VitB6 400g, dexamethasone 40g, Anisodamine 20g, general the State of Lu caine 200g, VitB12 3g, virazole 200 g, normal saline 85000 g.With above-mentioned each component mix homogeneously, divide to be filled in the glass notes bottle, the rear storage of sterilizing methods sterilization gets final product routinely.
Embodiment 4, get the raw materials ready by following component and weight ratio; VitB6 300g, dexamethasone 30g, Anisodamine 15g, lignocaine 30 g, VitB12 2 g, virazole 150 g, normal saline 65000 g.With above-mentioned each component mix homogeneously, divide to be filled in the glass notes bottle, the rear storage of sterilizing methods sterilization gets final product routinely.
Claims (2)
1. a pharmaceutical composition for the treatment of the varicella zoster virus disease is characterized in that: formulated by following component and weight ratio; VitB6: dexamethasone: Anisodamine: general the State of Lu caine: VitB12: virazole: normal saline=0.2-0.4:0.01-0.04:0.01-0.02:0.04-0.2:0.0005-0.003:0.1-0. 2:50-100.
2. a kind of pharmaceutical composition for the treatment of the varicella zoster virus disease according to claim 1 is characterized in that: described procaine is substituted by lignocaine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105708277A CN103040856A (en) | 2012-12-26 | 2012-12-26 | Medicine composition for treating varicella zoster virus disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105708277A CN103040856A (en) | 2012-12-26 | 2012-12-26 | Medicine composition for treating varicella zoster virus disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103040856A true CN103040856A (en) | 2013-04-17 |
Family
ID=48053868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105708277A Pending CN103040856A (en) | 2012-12-26 | 2012-12-26 | Medicine composition for treating varicella zoster virus disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103040856A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101628116A (en) * | 2009-08-10 | 2010-01-20 | 宋泽龙 | Pharmaceutical composition for treating herpes zoster |
-
2012
- 2012-12-26 CN CN2012105708277A patent/CN103040856A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101628116A (en) * | 2009-08-10 | 2010-01-20 | 宋泽龙 | Pharmaceutical composition for treating herpes zoster |
Non-Patent Citations (2)
| Title |
|---|
| 乔根弟，等: "带状疱疹的药物治疗观察", 《中国医学创新》, vol. 6, no. 3, 31 January 2009 (2009-01-31), pages 18 * |
| 陆秋莉，等: "山莨菪碱治疗糖尿病性多发性神经炎68例报告", 《中风与神经疾病杂志》, vol. 8, no. 3, 31 December 1991 (1991-12-31), pages 176 - 177 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101721474A (en) | Externally-applied liniment for treating psoriasis | |
| CN103040856A (en) | Medicine composition for treating varicella zoster virus disease | |
| CN100512846C (en) | A medicinal tincture and method for preparing the same | |
| CN105147796B (en) | A kind of Chinese medicine for treating type insomnia of having a guilty consicence | |
| CN103417608A (en) | Traditional Chinese medicine for treating gout | |
| CN101066278B (en) | Medicine use of energy mixture | |
| CN102335391B (en) | Fumigant for treating psoriasis | |
| CN104784482A (en) | Traditional Chinese medicine for treating chronic pyogenic osteomyelitis | |
| CN103989797B (en) | A kind of Chinese medicine preparation for the treatment of infant eczema | |
| Song et al. | Clinical study on surrounding acupuncture for herpes zoster | |
| CN103055275A (en) | Cough and asthma emplastrum capable of curing winter disease in summer | |
| Khan et al. | Vosstanovitel'noe lechenie detey s vospalitel'nymi zabolevaniyami tolstoy kishki | |
| CN101406529B (en) | Medicament for treating herpes zoster | |
| Niu et al. | The New understanding of Yin and Yang of TCM physiological model | |
| CN101375960A (en) | Chinese medicinal composition for treating eczema and cutitis of children | |
| CN104644828A (en) | External traditional Chinese medicine for treating eczema | |
| CN102145053A (en) | Traditional Chinese medicine composition with effects of warming channel and promoting circulation of qi | |
| CN205432147U (en) | Silica gel gasket of chinese herbal medicine health care | |
| CN102000297B (en) | Traditional Chinese medical composition for treating coronary heart disease | |
| CN201815004U (en) | Laser spinal therapeutic apparatus for diabetes | |
| CN103893343B (en) | Treat the Chinese medicine of climacteric complication, medicated bag and using method thereof | |
| CN103706041B (en) | For blood vessel and the magnet of multiple sclerosis | |
| CN101890039A (en) | Composite medicament used for treating herpes zoster | |
| CN104248675A (en) | External use medicinal liquor for treating traumatic injury | |
| CN102961720B (en) | Medicament for treating epidural post anesthesia lumbago and backache |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130417 |